Announced Sat, 5 Sept, 2026 · 19:34 IST
Sudarshan Pharma to acquire 9.5% stake in US biotech MedTherapy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+6.8%1-day move
₹39.49
prior close
₹40.25
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.8+2.8+2.8+2.8+6.8+1.4+0.0-1.2-1.2+1.3-5.4-1.2——
Up moveDown movePending
AI summary
Board approved acquiring 24,23,675.64 shares (9.50%) of MedTherapy Biotechnology Inc., a Boston-based cancer cell and gene therapy firm founded in 2018 by Harvard and ex-Novartis experts. Promoters will separately buy another 3% (1.50% each), taking combined holding to 12.5%. Cash deal in USD, expected to close by 31 March 2027. Aims to enter the US market, access customers and distribution, and expand into cell therapy. Not a related party transaction; needs RBI approval.
Likely market impact
Strategic entry into US cancer therapy space. Minority stake limits near-term financial impact but expands the company footprint to America.